Shridharani Sachin M
LUXURGERY, New York, New York.
Dermatol Surg. 2019 Oct;45(10):1285-1293. doi: 10.1097/DSS.0000000000001811.
Deoxycholic acid (DCA; ATX-101) injection was approved for the treatment of mild-to-moderate convexity associated with submental fat in 2015.
To evaluate the experience with DCA injections in a clinical practice setting.
This ongoing, prospective, single-center, single-arm, observational study evaluated 100 consecutive patients treated with subcutaneous DCA (2 mg/cm) injections (maximum 6 sessions at ≥1-month intervals). Treatment response was assessed using the clinician-reported submental fat rating scale (CR-SMFRS) and confirmed by independent physician review of photographs at 1 and 5 to 7 weeks after treatment.
Since the previous published report, 17 patients have undergone additional treatment sessions, with a total of 100 patients having undergone 195 treatment sessions: 41, 36, 14, 6, 2, and 1 patient underwent 1, 2, 3, 4, 5, and 6 sessions, respectively. Overall, 91.7% of patients in the single treatment session group and 100% in the multiple treatment session group had an improvement of ≥1 point on the CR-SMFRS. The mean (SD) duration of local edema, numbness, and tenderness after treatment was 7.1 (5.1), 27.9 (11.3), and 3.5 (3.5) days, respectively.
Deoxycholic acid injections were generally well tolerated, and ≥2 treatment sessions were required to achieve the desired aesthetic goal in a private practice setting.
2015年,脱氧胆酸(DCA;ATX-101)注射液被批准用于治疗与颏下脂肪相关的轻至中度凸度。
评估在临床实践中使用DCA注射的经验。
这项正在进行的前瞻性、单中心、单臂观察性研究评估了100例连续接受皮下注射DCA(2mg/cm)(最大6次,间隔≥1个月)治疗的患者。使用临床医生报告的颏下脂肪评分量表(CR-SMFRS)评估治疗反应,并在治疗后1周以及5至7周由独立医生对照片进行复查来确认。
自上次发表报告以来,17例患者接受了额外的治疗疗程,共有100例患者接受了195次治疗疗程:分别有41、36、14、6、2和1例患者接受了1、2、3、4、5和6次疗程。总体而言,单次治疗疗程组中91.7%的患者以及多次治疗疗程组中100%的患者在CR-SMFRS上改善了≥1分。治疗后局部水肿、麻木和压痛的平均(标准差)持续时间分别为7.1(5.1)天、27.9(11.3)天和3.5(3.5)天。
脱氧胆酸注射通常耐受性良好,在私人诊所环境中需要≥2次治疗疗程才能达到理想的美学目标。